SEC Form 4 · accession 0001209191-18-039710

Audentes Therapeutics, Inc. · BOLD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Louis G Lange

Director

Period of report

Jun 25, 2018

Accepted (ET)

Jun 27, 2018 · 6:51 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001628738

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Jun 25, 2018	S	18,860	$40.3635	D	386,939	D
Common Stock^F3	Jun 25, 2018	S	1,140	$41.3053	D	385,799	D
Common Stock^F4,F5	Jun 25, 2018	S	1,000	$40.783	D	8,555	I	By Adrienne M. MacMillan Revocable Trust
Common Stock^F6,F7	Jun 25, 2018	S	900	$40.7916	D	19,778	I	By Amygdala Lange Trust
Common Stock^F7	Jun 25, 2018	S	100	$41.46	D	19,678	I	By Amygdala Lange Trust
Common Stock^F8,F9	Jun 25, 2018	S	900	$40.7356	D	2,658	I	By Lange Minor's Trust
Common Stock^F9	Jun 25, 2018	S	100	$41.47	D	2,558	I	By Lange Minor's Trust
Common Stock^F10,F11	Jun 25, 2018	S	9,790	$40.8618	D	52,553	I	By Asset Management Ventures Fund, L.P.
Common Stock^F11	Jun 25, 2018	S	210	$41.27	D	52,343	I	By Asset Management Ventures Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F10Represents the average weighted sale price. The lowest price at which shares were sold was $40.265 and the highest price at which shares were sold was $41.25.
F11The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2Represents the weighted average sale price. The lowest price at which shares were sold was $40.20 and the highest price at which shares were sold was $41.19. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6), (8) and (10) to this Form 4.
F3Represents the weighted average sale price. The lowest price at which shares were sold was $41.205 and the highest price at which shares were sold was $41.41.
F4Represents the weighted average sale price. The lowest price at which shares were sold was $40.34 and the highest price at which shares were sold was $41.18.
F5The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F6Represents the weighted average sale price. The lowest price at which shares were sold was $40.28 and the highest price at which shares were sold was $41.22.
F7The reporting person's domestic partner is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
F8Represents the weighted average sale price. The lowest price at which shares were sold was $40.26 and the highest price at which shares were sold was $41.18.
F9The reporting person's domestic partner is the trustee of the Lange Minor's Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.